Miyoshi S, Tu A T
Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins 80523, USA.
Arch Biochem Biophys. 1996 Apr 1;328(1):17-25. doi: 10.1006/abbi.1996.0137.
A variety of snake venoms was tested for the ability to inhibit the binding of antagonists to specific muscarinic acetylcholine receptors (mAChRs); the highest activity was found in the venom of Naja naja sputatrix. The active principle in this venom was isolated by column chromatography on Sephadex G-50, Sephadex G-150, and CM-Sephadex C-25. The final preparation was homogeneous as determined by polyacrylamide gel electrophoresis and HPLC; about sevenfold purification was achieved with a yield of 12%. The isolated active component, which was designated "muscarinic inhibitor," was found to displace various antagonists from rat synaptosomal membranes, which contain all subtypes of mAChRs. The m1 and m2 recombinant human receptors were also competitive with N. naja sputatrix muscarinic inhibitor. This antagonist-displacing action was dose dependent, but was independent of the reaction temperature. The isolated muscarinic inhibitor was determined to be a 13.6 kDa, monomeric, neutral protein and to have an N-terminal amino acid sequence which is highly homologous with phospholipase A2 from the venoms of genus Naja. N. naja sputatrix muscarinic inhibitor could hydrolyze phosphatidylcholine in a dose- and temperature-dependent manner. This phospholipase A2 enzymatic activity was augmented by the addition of the calcium ion, while it was almost completely abolished by a competitive inhibitor of phospholipase A2 enzymes. However, the antagonist-displacing activity was only slightly affected by these agents. The treatment of the muscarinic inhibitor with p-bromophenacyl bromide, which selectively modifies the histidine residue in the catalytic site of a phospholipase A2 enzyme, caused completed elimination of both activities. These findings indicate that N. naja sputatrix muscarinic inhibitor is a protein with two distinct activities, phospholipase and antagonist displacement, the active centers of which may be in close physical proximity for both actions. This is the first finding that a phospholipase A2 is an inhibitor of the muscarinic receptor.
测试了多种蛇毒抑制拮抗剂与特定毒蕈碱型乙酰胆碱受体(mAChRs)结合的能力;发现眼镜蛇(Naja naja sputatrix)毒液的活性最高。通过在葡聚糖凝胶G - 50、葡聚糖凝胶G - 150和CM - 葡聚糖凝胶C - 25上进行柱色谱法,从这种毒液中分离出了活性成分。通过聚丙烯酰胺凝胶电泳和高效液相色谱法测定,最终制剂是均一的;实现了约7倍的纯化,产率为12%。分离出的活性成分被命名为“毒蕈碱抑制剂”,发现它能从含有所有mAChR亚型的大鼠突触体膜上置换出各种拮抗剂。m1和m2重组人受体也与眼镜蛇毒蕈碱抑制剂具有竞争性。这种拮抗剂置换作用呈剂量依赖性,但与反应温度无关。经测定,分离出的毒蕈碱抑制剂是一种13.6 kDa的单体中性蛋白,其N端氨基酸序列与眼镜蛇属毒液中的磷脂酶A2高度同源。眼镜蛇毒蕈碱抑制剂能够以剂量和温度依赖性方式水解磷脂酰胆碱。添加钙离子可增强这种磷脂酶A2的酶活性,但磷脂酶A2酶的竞争性抑制剂几乎可使其完全丧失活性。然而,这些试剂对拮抗剂置换活性的影响很小。用对溴苯甲酰溴处理毒蕈碱抑制剂,该试剂可选择性修饰磷脂酶A2酶催化位点中的组氨酸残基,导致两种活性完全消除。这些发现表明,眼镜蛇毒蕈碱抑制剂是一种具有两种不同活性的蛋白质,即磷脂酶活性和拮抗剂置换活性,其两种活性的活性中心在物理位置上可能紧密相邻。这是首次发现磷脂酶A2是毒蕈碱受体的抑制剂。